CD2: T-cell surface antigen CD2
CD2 interacts with lymphocyte function-associated antigen CD58 (LFA-3) and CD48/BCM1 to mediate adhesion between T-cells and other cell types.
- Drugs that act on it: 2
- Approved: 1
- In phases 1 to 3: 1
- Sponsors: 2
Who is on it, and how far along
Every drug ChEMBL records acting on CD2, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 1
- Protein or peptide 1
| Alefacept | Approved | Astellas Pharma | Protein or peptide | InhibitorT-cell surface antigen CD2 inhibitor | 0 |
| Siplizumab | Phase 2 | ITB-Med LLC | Antibody | InhibitorT-cell surface antigen CD2 inhibitor | 7 |
| A Study Comparing Siplizumab With Rabbit Anti-Thymocyte Globulin to Help the Body Accept a Kidney Transplant | Siplizumab | Phase 2 | Recruiting | ITB-Med LLC | Apr 2, 2026 |
| Tolerance Through Mixed Chimerism (Sip-Tego) | Siplizumab | Early phase 1 | Active, not recruiting | Tatsuo Kawai, MD, PhD | May 14, 2025 |
| A Study of SIPLIZUMAB in AILD and LT Patients | Siplizumab | Phase 1 | Recruiting | Elizabeth C. Verna | Jun 12, 2024 |
| Evaluate the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa. | Siplizumab | Early phase 1 | Recruiting | University of Alabama at Birmingham | Mar 22, 2024 |
| A Study of TCD601 in the Induction of Tolerance in de Novo Liver Transplantation | Siplizumab | Phase 2 | Active, not recruiting | ITB-Med LLC | Aug 31, 2023 |
| Delayed Tolerance Through Mixed Chimerism | Siplizumab | Phase 1 / Phase 2 | Recruiting | Massachusetts General Hospital | Jun 12, 2023 |
| Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGH | Siplizumab | Phase 1 | Active, not recruiting | Massachusetts General Hospital | Sep 7, 2020 |
- Hypothyroidism0.46
- Rheumatoid arthritis0.43
- Myxedema0.38
- Psoriasis vulgaris0.38
- Immune system disorder0.37
- Pain0.37
- Thyroid gland disorder0.33
- Autoimmune thyroid disease0.31
- Psoriasis0.25
- Kidney disorder0.23
- Graves disease0.22
- Ankylosing spondylitis0.21
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2040, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P06729, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets